Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Phosphatidic Acid (PA) can Displace PPARα/LXRα Binding to The EGFR Promoter Causing its Transrepression in Luminal Cancer Cells.
Sci Rep. 2015 Oct 23;5:15379. doi: 10.1038/srep15379.
Sci Rep. 2015.
PMID: 26493292
Free PMC article.
Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3).
Henkels KM, Farkaly T, Mahankali M, Segall JE, Gomez-Cambronero J.
Henkels KM, et al. Among authors: farkaly t.
J Mol Biol. 2011 May 20;408(5):850-62. doi: 10.1016/j.jmb.2011.03.017. Epub 2011 Mar 22.
J Mol Biol. 2011.
PMID: 21414324
Free PMC article.
Item in Clipboard
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Kennedy EM, Denslow A, Hewett J, Kong L, De Almeida A, Bryant JD, Lee JS, Jacques J, Feau S, Hayes M, McMichael EL, Wambua D, Farkaly T, Rahmeh AA, Herschelman L, Douglas D, Spinale J, Adhikari S, Deterling J, Scott M, Haines BB, Finer MH, Ashburn TT, Quéva C, Lerner L.
Kennedy EM, et al. Among authors: farkaly t.
Nat Commun. 2022 Oct 7;13(1):5907. doi: 10.1038/s41467-022-33599-w.
Nat Commun. 2022.
PMID: 36207308
Free PMC article.
Item in Clipboard
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Quéva C.
Haines BB, et al. Among authors: farkaly t.
Cancer Immunol Res. 2021 Mar;9(3):291-308. doi: 10.1158/2326-6066.CIR-20-0609. Epub 2020 Dec 22.
Cancer Immunol Res. 2021.
PMID: 33355229
Item in Clipboard
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Kennedy EM, Farkaly T, Grzesik P, Lee J, Denslow A, Hewett J, Bryant J, Behara P, Goshert C, Wambua D, De Almeida A, Jacques J, Deavall D, Rottman JB, Glorioso JC, Finer MH, Haines BB, Quéva C, Lerner L.
Kennedy EM, et al. Among authors: farkaly t.
Mol Ther Oncolytics. 2020 Aug 8;18:476-490. doi: 10.1016/j.omto.2020.08.004. eCollection 2020 Sep 25.
Mol Ther Oncolytics. 2020.
PMID: 32953982
Free PMC article.
Item in Clipboard
Cite
Cite